Initiate a Phase 2 trial in patients with amyotrophic lateral sclerosis
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- October 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the fourth quarter, we plan to initiate a Phase 2 trial in patients with amyotrophic lateral sclerosis (ALS).”
What we found
Evidence strength A What the grades mean
The company committed to starting the Phase 2 ALS trial in Q2 2022, but later filings confirm the trial was initiated in October 2022.
-
A Corcept Therapeutics Inc. 10-K filed 2023-02-28
“Following these compelling results, in October 2022 we initiated a Phase 2 trial of dazucorilant (the “DAZALS” trial) in patients with ALS.” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 23 Feb 2021
Deadline 31 Dec 2021 (“In the fourth quarter”) · wording expected
-
Version 2 · stated 15 Feb 2022
Deadline 30 Jun 2022 (“second quarter”) · wording expected
“we plan to start a Phase 2 trial in patients with amyotrophic lateral sclerosis (ALS) in the second quarter.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 trial in patients with ALS
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CORT-024265 · Corrections policy